Panitumumab

EGF is a magnesiotropic hormone. Locally produced pro-EGF is cleaved at the basolateral membrane of distal convoluted tubule (DCT) cells and, via the basolateral EGFR, sustains activity of the apical Mg2+ channel TRPM6 that mediates distal magnesium reabsorption (Groenestege, J Clin Invest 2007; Ellison, NDT 2008). Panitumumab blocks EGFR and withdraws this tonic stimulus, so TRPM6-mediated reabsorption falls and magnesium is inappropriately lost in the urine — a renal magnesium-wasting tubulopathy with high fractional excretion of magnesium despite hypomagnesemia and preserved GFR (Tejpar, Lancet Oncol 2007 demonstrated a renal reabsorption defect on 24-h urine and IV magnesium-load testing). The magnesium deficit in turn drives secondary hypocalcemia (impaired PTH secretion/action) and renal potassium wasting. Panitumumab appears to cause more magnesium wasting than cetuximab; the reason is not fully established but is plausibly related to sustained high-affinity EGFR blockade with q2wk dosing rather than to any structural nephrotoxicity.

Most often an asymptomatic laboratory finding of a slowly falling serum magnesium detected on routine monitoring. When magnesium is markedly low, patients can develop fatigue, muscle cramps, weakness, tremor, paresthesias, tetany, and — in severe cases — neuromuscular irritability, seizures, or cardiac arrhythmias including QT prolongation. It is frequently accompanied by secondary hypocalcemia and hypokalemia that track the magnesium deficit and are refractory until magnesium is corrected.

Oral magnesium for mild cases, though its use is limited by diarrhea. Moderate-to-severe or symptomatic hypomagnesemia usually requires recurrent IV magnesium repletion (e.g., magnesium sulfate infusions), often weekly, because the renal leak continues while therapy is ongoing. Always correct magnesium first — secondary hypocalcemia and hypokalemia stay refractory until the magnesium deficit is repleted. Hold or interrupt panitumumab for severe (grade 3-4) or symptomatic hypomagnesemia and reassess; the antibody itself needs no renal dose reduction.Lesion-level management framework

No renal dose adjustment. Panitumumab is an IgG2 monoclonal antibody cleared by target-mediated and reticuloendothelial catabolism, not renal excretion, and GFR is preserved, so eligibility and dosing are unchanged in CKD. The clinical challenge is magnesium (and secondary calcium/potassium) repletion, not adjusting the antibody dose.

Not dialyzable. At roughly 147 kDa the IgG2 antibody vastly exceeds any dialysis membrane cutoff and is not removed by hemodialysis (the repleted magnesium is dialyzable, but the drug is not).

Renal Mg wasting from EGFR blockade shows inappropriately high urinary magnesium (FEMg typically >2-4%) despite hypomagnesemia, with normal creatinine/GFR and a temporal link to dosing. Distinguish from GI losses (diarrhea) where the kidney appropriately conserves Mg (low FEMg); PPI-induced hypomagnesemia (a very common co-medication); cisplatin tubulopathy (also renal Mg wasting but accompanied by AKI/rising creatinine); and Gitelman syndrome or thiazide/loop diuretics (distal Mg plus K wasting). The key discriminator for panitumumab is renal Mg wasting with preserved GFR.